Abstract
In this editorial we comment on the article by Jiang et al. We focus on the EncephalApp Stroop test which is an innovative, smartphone-based tool specifically designed for screening minimal hepatic encephalopathy (MHE) in cirrhosis patients. Traditional MHE screening methods, while highly sensitive and specific, are often complex, time-consuming, and require controlled environmental conditions, limiting their widespread clinical use. The EncephalApp Stroop test simplifies the screening process, enhances diagnostic efficiency, and is applicable across diverse cultural contexts. However, the combination of additional biomarkers could further improve diagnostic accuracy. Despite its promising potential, more multicenter clinical studies are required to validate its effectiveness and applicability on a global scale.